BioBytes: AI-Related Deals In Q2 2024

 
• By David Wild

Dominated by Xaira Therapeutics' $1bn venture financing, Q2 2024 was also notable for sizeable public offerings by Alumis and Recursion Therapeutics in the US and XtalPi Technology in Hong Kong, as well as a $142m seed round for EvolutionaryScale.     

Bio Bytes
• Source: Shutterstock

More from Market Intelligence

More from In Vivo